It will therefore be interesting to investigate the possible outcome, in terms of G6PD regulation and anti-tumor effects, when combining 1,25(OH)2D3 with either a p53 activator such as nutlin-3a, or a G6PD inhibitor, e.g., dehydroepiandrosterone. This evidence concerns the gene TP53 and neoplasm.